US Patent 7910708 Anti-IL13 human antibodies
Patent 7910708 was granted and assigned to Novartis on March, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+332 characters)
Article
Patent abstract
The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Emma Campbell0
Gunars Valkirs0
Joe Buechler0
Sofia Parveen0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07910708 Anti-IL13 human antibodies US Patent 7910708 Anti-IL13 human antibodies
Infobox
Patent Number
07910708
Patent Number
7910708
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07910708 Anti-IL13 human antibodies
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07910708
Date of patent
March 22, 2011
Patent application number
12091020
Date Filed
October 19, 2006
Patent primary examiner
Find more entities like US Patent 7910708 Anti-IL13 human antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
